Top Markets
Coin of the day
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.

BML
Classifica tra le azioni #22879
Established in 1944 and headquartered in Lublin, Poland, BIOMED-LUBLIN... Established in 1944 and headquartered in Lublin, Poland, BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. is a biotechnology enterprise engaged in the manufacturing and distribution of pharmaceutical products, medical devices, and laboratory reagents throughout Poland. The company's range of prescription medications includes Distreptaza, utilized in gynecology for addressing chronic inflammatory conditions of the uterine appendages and hemorrhoids. Onko BCG 50 is prescribed for the treatment of superficial (non-muscle invasive) bladder tumors. For passive immunity against hepatitis B, they provide GAMMA anty HBs 200. Additionally, GAMMA anty-D 50 and GAMMA anty-D 150 are Anti D (Rho) immunoglobulin formulations crucial for preventing hemolytic disease in newborns. BioTrombina 400 offers localized control for significant bleeding, and the Anti-Tuberculosis Vaccine BCG 10 is integral to tuberculosis prevention efforts. Beyond pharmaceuticals, BIOMED-LUBLIN supplies a variety of medical and laboratory-grade items. These encompass Ram blood for laboratory applications; Stonebrink medium for the diagnosis of bovine Mycobacterium tuberculosis; and specific Löwenstein-Jensen media, including one adapted for assessing Mycobacterium tuberculosis's drug susceptibility and another containing glycerol for its identification. Their offerings also extend to Ox Thrombin for in-vitro diagnostics and lyophilized preparations, alongside rabbit plasma. Furthermore, the company offers an extensive catalog of reagents. This includes various sera (horse, bovine, calf), essential solutions like trypsin, PBS fluid, Hanks fluid, and Parker's fluid, as well as diverse culture media such as Eagle 1959, RPMI 1640, and Ogawa medium. Completing their reagent portfolio are pseudo cholinesterase, Ox fibrinogen, and rabbit complements.
Prezzo delle azioni
$1.32
Ultima sincronizzazione: 2023-08-14
Capitalizzazione di mercato
$81.94M
Variazione (1 giorno)
-0.36%
Variazione (1 anno)
0.00%
Paese
PL
Scambia BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML)

Categoria

Utile per BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH